Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MIGI - Mawson Infrastructure Group Inc


IEX Last Trade
1.3
-0.060   -4.615%

Share volume: 455,891
Last Updated: Fri 30 Aug 2024 09:59:54 PM CEST

PREVIOUS CLOSE
CHG
CHG%

$1.36
-0.06
-4.41%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Performance
5 Days
-21.21%
1 Month
5.69%
3 Months
0   0%
6 Months
-28.96%
1 Year
51.18%
2 Year
-69.06%
Key data
Stock price
$1.30
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.46 - $4.40
52 WEEK CHANGE
$0.82
MARKET CAP 
24.120 M
YIELD 
N/A
SHARES OUTSTANDING 
18.554 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$510,042
AVERAGE 30 VOLUME 
$1,454,916
Company detail
CEO: Noam Danenberg
Region: US
Website: https://www.wizepharma.com/
Employees: 1
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

wize pharma, inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including des. wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as lo2a, a drug developed for the treatment of des, and other ophthalmological illnesses, including cch and sjögren's syndrome (sjögren's). lo2a is currently registered and marketed by its inventor in germany and switzerland for the treatment of des, in hungary for the treatment of des, cch and sjögren's and in the netherlands for the treatment of des and sjögren's. wize's strategy involves engaging local or multinational distributors to handle the distribution of lo2a. wize has finished a phase ii trial of lo2a for patients with cch and is currently conducting a phase iv study for lo2a for des in patients with sjögren's.

Recent news